RxDoctor Payments Data

Danielle Demkovitz

Nurse Practitioner · Morristown, NJNPI 1528714664

Payments from drug & device makers

$5,175in general payments, 2019–2025

Across 287 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$634
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$474
  • Novo Nordisk$437
  • Merck$381
  • Pfizer$356
  • Novartis$307
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$5,175100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,175 in reported general payments places this provider in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$18,326
Medicare patients
158
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$169,167
XareltoRivaroxaban29$41,469
Repatha SureclickEvolocumab37$28,294
VascepaIcosapent Ethyl16$16,541
OzempicSemaglutide14$12,748
EdarbiAzilsartan Medoxomil11$8,122
BrilintaTicagrelor11$6,276
Icosapent Ethyl13$3,356
Rosuvastatin Calcium218$3,106
Metoprolol Succinate178$2,803
Ezetimibe85$1,824
Valsartan61$1,608
Atorvastatin Calcium157$1,412
Amlodipine Besylate99$781
Carvedilol47$634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$356$169,167132 claims
Johnson & JohnsonXarelto$148$41,46929 claims
Novo NordiskOzempic$437$12,74814 claims
AstraZenecaBrilinta$195$6,27611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →